Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Incyte Corporation (INCY) vs ON Holding AG (ONON) Price & Performance

Incyte CorporationTrade
ON Holding AGTrade

Price performance (Past 24H)

Key statistics

Incyte Corporation vs ON Holding AG — how do they compare? Incyte Corporation trades at $120.54 (market cap $24.54B), while ON Holding AG trades at $31.02 (market cap $10.33B). The key difference: Incyte Corporation is far larger — about 2.4× ON Holding AG's market cap, and Incyte Corporation is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals.

INCYONON
Market Cap
$24.54B$10.33B
Sector
HealthTechnology
52-Week High
$129.93$50.63
52-Week Low
$81.61$30.91
Enterprise Value
$20.04B$9.47B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Incyte Corporation

Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.

Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.

ON Holding AG

ONON stock plunged 19.93% to $31.05 after Q2 2026 results, driven by a revenue miss and lowered full-year growth guidance. Despite beating EPS estimates in recent quarters, the company faces wholesale channel softness and cautious consumer spending. Technical indicators are bearish, with the price near key support at $30, while fundamentals show strong profitability margins and positive cash flow trends. Analyst sentiment remains largely bullish with a $52.86 consensus target, but near-term volatility persists.

The outlook is mixed: long-term growth potential exists via direct-to-consumer strength and margin expansion, but investors face risks from guidance uncertainty and competitive pressures. The sharp sell-off may present a buying opportunity for patient investors, though volatility could continue until wholesale trends stabilize.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY

About ON Holding AG

ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.

Read more on ONON